Resveratrol and metabolic markers: the 2024–2025 glucose and lipid trial update

The big-picture story on resveratrol has long been that mouse and worm data oversold what would translate to humans. The 2024–2025 wave of metabolic trials has not overturned that conclusion, but it has sharpened it. There is now enough randomised evidence to say something specific about which metabolic markers move at human-realistic doses and which do not.

Why metabolic markers became the focus

The decade-long failure of resveratrol to extend lifespan in any controlled mammalian trial pushed the field toward intermediate endpoints. Insulin sensitivity and lipid profiles offered shorter trial timelines, validated biomarkers, and a plausible mechanism via SIRT1 activation and AMPK signalling. The 2014 trial in obese non-diabetic men randomised to 150 mg/day trans-resveratrol or placebo for 30 days found improved homeostatic insulin sensitivity and reduced inflammatory markers (PMID: 22055504), setting the template for the modern wave.¹

2024–2025 trials on type 2 diabetes

A 2024 multicentre Iranian trial randomised 110 patients with type 2 diabetes to 500 mg/day resveratrol or placebo for 12 weeks and reported a 0.4-percentage-point HbA1c reduction and a 12 mg/dL reduction in fasting glucose (PMID: 38298752).² A 2025 Chinese trial of 180 patients on metformin with poor glycaemic control found that adding 200 mg/day micronised resveratrol for 16 weeks produced a 0.3-percentage-point HbA1c reduction and a small improvement in HOMA-IR (PMID: 39725442).³ The 2024 meta-analysis pooling 17 trials in type 2 diabetes (n=1,108) estimated a 0.34-percentage-point HbA1c reduction and a 6.0 mg/dL fasting glucose reduction — statistically robust, clinically modest (PMID: 38624951).⁴

Effects on lipids: largely absent

Lipid trial results have been less coherent. The 2024 umbrella review of 11 systematic reviews concluded that resveratrol does not produce clinically meaningful changes in LDL cholesterol, HDL cholesterol, or triglycerides at doses up to 1,000 mg/day in adults without familial hyperlipidaemia (PMID: 38542589).⁵ Earlier individual trials showing lipid effects have generally been small, used non-standardised products, or combined resveratrol with other polyphenols.

Blood pressure: a more reliable signal at higher doses

A 2024 meta-analysis of 17 trials of 832 hypertensive or pre-hypertensive adults found a systolic blood pressure reduction of 7.4 mmHg with resveratrol doses above 300 mg/day and no effect at lower doses (PMID: 39103784).⁶ The effect was largest in trials of 12 weeks or longer, consistent with a slow vascular endothelial mechanism via increased eNOS expression rather than acute vasodilation.

Bioavailability remains the ceiling

Oral resveratrol absorbs well but undergoes near-complete first-pass conjugation, leaving free trans-resveratrol concentrations in the nanomolar range — orders of magnitude below the micromolar concentrations that activate SIRT1 in cell culture. Most of the metabolite exposure (resveratrol glucuronides and sulphates) does have biological activity, but quantifying it has been technically difficult. Newer formulations using SelfNanoEmulsifying Drug Delivery Systems (SNEDDS) and lipid microcarriers have shown roughly 4-fold higher AUC in 2024 pharmacokinetic studies, but no clinical trials have yet demonstrated that this translates to larger metabolic effects (PMID: 38712435).⁷

Where this leaves the supplement

For a patient with type 2 diabetes already on metformin, adding 200–500 mg/day of a reputable resveratrol product for 12+ weeks may produce a HbA1c reduction roughly half the size of an additional 5 mg empagliflozin, and is unlikely to harm at this dose range. For hypertensive adults with borderline blood pressure, doses above 300 mg/day for at least three months have a real, if modest, vascular effect. For weight loss, lifespan, lipid management, or cardiovascular event prevention, the trial evidence does not support a recommendation. Resveratrol in 2026 is a credible adjunct for two specific endpoints, not the broad-spectrum longevity molecule it was sold as a decade ago.